| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | RECRUITING | PHASE3 | 2025-10 | 2031-03 | 2030-10 |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | RECRUITING | PHASE1, PHASE2 | 2025-09 | 2029-05 | 2029-05 |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | RECRUITING | PHASE2, PHASE3 | 2023-10-31 | 2028-01-15 | 2027-01-15 |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | RECRUITING | PHASE2 | 2023-07-03 | 2029-01-31 | 2026-01-31 |
| NCT05787587 | A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2023-04-05 | 2027-05 | 2026-10 |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | RECRUITING | PHASE1 | 2021-04-14 | 2027-03-30 | 2026-12-31 |
| NCT03947385 | Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | RECRUITING | PHASE1, PHASE2 | 2019-06-28 | 2027-03-31 | 2026-12-31 |